基本信息
views: 280
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Disis is a Professor of Medicine and Adjunct Professor of Pathology and Obstetrics and Gynecology at the University of Washington (UW), and a Member of the Fred Hutchinson Cancer Research Center (FHCRC). She is the Associate Dean for Translational Science in the UW School of Medicine. Dr. Disis received her M.D. from the University of Nebraska Medical School and completed a residency and chief residency in Internal Medicine at the University of Illinois in Chicago. Her fellowship in oncology was completed at UW/FHCRC. Dr. Disis is an expert in breast and ovarian cancer immunology and translational research. She is one of the pioneering investigators who discovered that HER-2/neu is a tumor antigen. Her work has led to several clinical trials which evaluate boosting immunity to HER-2/neu with cancer vaccines. Dr. Disis is a member of Alpha Omega Alpha and the American Society of Clinical Investigation. She is the Editor in Chief for JAMA Oncology, and is a member of several committees and task forces for both the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). She is also the Director of the Institute of Translational Health Sciences and the Director for the Center for Translational Medicine in Women’s Health at the UW. Her multifaceted research program within the Tumor Vaccine Group includes the discovery of new antigens for common solid tumors, the development of vaccine and cellular therapy targeting specific antigens, and immunodiagnostics.
Her research interest is in the discovery of new molecular immunologic targets in solid tumors for the development of vaccine and cellular therapy for the treatment and prevention of those malignancies. In addition, her group evaluates the use of the immune system to aid in the diagnosis of cancer and develops novel assays and approaches to quantitate and characterize human immunity. She holds several patents in the field of targeted cancer immunotherapy and immune-based diagnostics.
Selected Publications
Lu, H., Knutson, K.L., Gad, E., and Disis, M.L.: The tumor antigen repertoire identified in tumor bearing neu transgenic mice predicts human tumor antigens. Cancer Research, Oct. 1; 66(19):9754-61, 2006.
Dang, Y., Knutson, K.L., Goodell, V., delaRosa, C., Salazar, L.G., Higgins, D., Childs, J., and Disis, M.L.: Tumor antigen specific T cell expansion is greatly facilitated by in vivo priming. Clin Cancer Research, Mar 15; 13(6):1883-1891, 2007.
Inokuma, M., delaRosa, C., Schmitt, C., Haaland, P., Siebert, J., Petry, D., Tang, M.X., Suni, M.A., Ghanekar, S.A., Gladding, D., Dunne, J.F., Maino, V.C., Disis, M.L., and Maecker, H.T.: Functional T cell responses to tumor antigens in breast cancer patients have a distinct phenotype and cytokine signature, Journal of Immunology, 179:2627-2633, 2007.
Goodell, V., Waisman, J., Salazar, L.G., dela Rosa, C., Link, J., Coveler, A.L., Webster, W., Childs, J. S., Fintak, P.A., Higgins, D.M., and Disis, M.L. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Molecular Cancer Therapeutics, 7(3):449-54, 2008.
Maecker, H.T., Hassler, J., Payne, J.K., Summers, A., Comatas, K., Ghanayem, M., Morse, M.A., Clay, T.M., Lyerly, H.K., Bhatia, S., Ghanekar, S.A., Maino, V.C., delaRosa, C., and Disis, M.L.: Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides. BMC Immunology, 9:9, 2008.
Park, K.H., Gad, E., Goodell, V., Dang, Y., Wild, T., Higgins, D. Fintak, P., Childs, J., delaRosa, C, and Disis, M.L.: Insulin like growth factor binding protein 2 is a target for the immunomodulation of breast cancer. Cancer Research, 68 (20):1-10, 2008.
Disis, M.L., Wallace, D. Gooley, T.A., Dang, Y., Slota, M., Lu, H., Coveler, A., Childs, J., Higgins, D., Fintak, P., delaRosa, C., Tietje, K., Link, J., Waisman, J., and Salazar, L.G.: Concurrent trastuzumab and HER-2/neu specific vaccination in patients with metastatic breast cancer. Journal of Clin Oncol, Oct 1;27(28):4685-4692, 2009.
Lu, H, Wagner, WM, Gad, E, Yang, Y, Duan, H, Amon, LM, Van Denend, N, Larson, ER, Chang, A, Tufvesson, H, and Disis, ML: Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade, J Immunol, 184 (9):5360-5367, 2010.
Research Interests
Papers共 466 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Molecular aspects of medicine (2024): 101292-101292
Kirsten Bibbins-Domingo,Annette Flanagin, Caroline Sietmann,Robert O. Bonow, Ann Marie Navar,Kanade Shinkai,Mya L. Roberson,John Z. Ayanian, Ninez Ponce,Sharon K. Inouye, Raegan W. Durant,Melissa A. Simon,
JAMA oncologyno. 5 (2024): 571-572
crossref(2023)
CANCER RESEARCHno. 7 (2023)
Cancer Researchno. 5_Supplement (2023): PD12-05
Cancer Researchno. 5_Supplement (2023): P2-02
crossref(2023)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn